Stocks
Paratek Intl CorpPRTK
HealthcareBiotechnology
A biopharmaceutical company focused on developing and commercializing innovative therapies, primarily in the infectious disease space. Its lead product, Nuzyra, is an antibiotic approved for skin infections and community-acquired bacterial pneumonia. Investors track the company for its commercial execution and pipeline developments in antibiotic resistance.
Congressional Interest in Paratek Intl Corp (PRTK)
1 member of Congress has disclosed 1 trade in Paratek Intl Corp (PRTK), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading PRTK?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-01-29 | Tom Price | sell | $15K-$50K |